Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine

The candidate vaccine HZ/su is being developed to prevent herpes-zoster disease (HZ). HZ occurrence is attributed to declines in varicella-zoster virus (VZV) specific T-cell immunity. HZ/su contains VZV antigen, gE, and Adjuvant System AS01(B) (liposome-based formulation of MPL and QS-21). In clinic...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Hum Vaccin Immunother
Asıl Yazarlar: Fochesato, Michel, Dendouga, Najoua, Boxus, Mathieu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2016
Konular:
Short Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4994747/
https://ncbi.nlm.nih.gov/pubmed/26933767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2016.1154247
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller